Compounded tirzepatide has become one of the most searched weight loss topics online, and for good reason. Tirzepatide is a dual GLP-1/GIP receptor agonist that produced some of the most impressive weight loss results ever seen in clinical trials.
In the SURMOUNT-1 study, participants on the highest dose lost an average of over 22% of their body weight over 72 weeks. Those are numbers that were once only achievable through bariatric surgery.
But the pathway to getting compounded tirzepatide is not as simple as it used to be, and there is a lot of outdated or misleading information floating around.
The regulatory picture has shifted significantly since 2024, and patients considering this option need to understand what has changed, what is still legal, and how to do it safely.
This article walks through the current state of compounded tirzepatide, who it may be appropriate for, and how the prescription process works through a telehealth provider.
What Is Compounded Tirzepatide, Exactly?
Let’s start with the basics. Brand-name tirzepatide is sold as Mounjaro (for type 2 diabetes) and Zepbound (for weight management), both manufactured by Eli Lilly. These are FDA-approved products.
Compounded tirzepatide is a version of the same active ingredient, prepared by a licensed compounding pharmacy rather than the brand-name manufacturer. Compounding pharmacies produce medications tailored to individual patient needs, and they operate under FDA oversight through either Section 503A (state-licensed pharmacies) or Section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act.
Here is the important distinction that many articles skip over: compounded versions are produced in FDA-registered facilities, but they are not FDA-approved as brand-name drugs. The active ingredient is the same, but the final product has not gone through the same approval process as Mounjaro or Zepbound. This matters, and any provider or website that glosses over this difference is not giving you the full picture.
The Regulatory Reality in 2025 and Beyond
This is where things get complicated, and where most online content falls short.
During 2022 through 2024, tirzepatide was on the FDA’s drug shortage list, which created a temporary window during which compounding pharmacies were permitted to produce copies of the drug to help meet patient demand. That shortage designation was resolved in October 2024, and the FDA subsequently issued enforcement timelines for compounders to wind down production.
Section 503B outsourcing facilities were required to stop compounding tirzepatide by March 2025. Section 503A state-licensed pharmacies had an earlier deadline, though ongoing litigation between the Outsourcing Facilities Association and the FDA has created some complexity around enforcement timelines.
So where does that leave patients today? Section 503A pharmacies can still legally compound tirzepatide for individual patients when a licensed provider writes a prescription with documented clinical justification. The key word there is “individual.” Bulk production and mass distribution are no longer permitted the way they were during the shortage.
A compounded version must represent a meaningful modification from the commercially available product, or the patient must have a documented clinical need that the brand-name product cannot meet.
The availability and legal status of compounded tirzepatide is subject to FDA regulation and may change. This article reflects information available at the time of publication. Always consult a licensed provider.
Who Is a Candidate for Compounded Tirzepatide?
Not everyone who wants tirzepatide will be prescribed it, and that is how it should be. This is a medication with real physiological effects that requires proper medical evaluation.
Generally, tirzepatide may be appropriate for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. Your provider will evaluate your full medical history during your consultation.
There are also important contraindications. Tirzepatide carries an FDA boxed warning regarding thyroid C-cell tumors observed in rodent studies. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not use this medication. Your provider should ask about this directly, and if they don’t, bring it up yourself.
For patients who are exploring their options between different GLP-1 medications, it may also help to understand how compounded semaglutide works as an alternative pathway. Some patients do better on one medication than the other based on side effect tolerance, cost, and individual response.
How the Telehealth Prescription Process Works
If you have decided you want to explore compounded tirzepatide, working with a telehealth provider is one of the most straightforward paths. Here is how it typically unfolds.
You begin with an online intake form. This covers your medical history, current medications, weight and height, previous weight loss attempts, and any relevant conditions. Be honest and thorough. The provider is using this information to make a clinical decision about your safety, not to judge you.
Next comes the provider consultation. A licensed healthcare professional reviews your intake and meets with you, either asynchronously (reviewing your submitted information and responding) or through a live telehealth visit.
During this step, the provider determines whether tirzepatide is medically appropriate for your situation. They will explain dosing, expected side effects, and what the treatment timeline looks like.
If the provider determines you are a good candidate, they write a prescription that is sent to a licensed compounding pharmacy. The pharmacy prepares your medication and ships it to your home, usually within a few business days.
One thing worth verifying: ask about the pharmacy’s credentials. A trustworthy provider will work with pharmacies that can provide a Certificate of Analysis for each batch, confirming the potency and purity of the medication you are receiving.
What to Expect Once You Start
Tirzepatide is administered as a subcutaneous injection once per week. The dosing follows a titration schedule, typically starting at 2.5 mg and increasing gradually every four weeks depending on your tolerance and response. Most providers will walk you through the injection process and provide clear instructions, so even if you have never self-injected before, it is manageable.
The most common side effects are gastrointestinal: nausea, diarrhea, constipation, and reduced appetite. These tend to be most noticeable during the first few weeks at each new dose level and usually improve as your body adjusts. If side effects become difficult to manage, your provider can slow the titration or adjust your protocol. You should not try to manage this on your own.
Many patients notice a meaningful reduction in appetite within the first week or two.
Significant weight loss usually becomes visible between weeks four and eight, with continued progress over several months. Individual timelines vary, and patience matters here. This is not a medication that delivers overnight results, but the clinical data supports substantial long-term outcomes for patients who stay on protocol.
Red Flags to Watch For
The surge in demand for tirzepatide has attracted bad actors. Protect yourself by watching for a few warning signs.
Avoid any service that offers tirzepatide without requiring a medical evaluation. This is a prescription medication, and there is no legal way to obtain it without a provider reviewing your health history.
Be skeptical of platforms selling “oral tirzepatide” tablets or drops. As of 2026, there is no FDA-approved oral formulation of tirzepatide, and anything marketed as such should be treated with extreme caution.
Also watch out for pricing that seems dramatically lower than the market. Compounded tirzepatide has real costs associated with pharmaceutical-grade ingredients, sterile compounding, and quality testing. If the price does not reflect that, something is being cut.
If you want to understand how your provider ensures medication quality, ask whether they work with FDA-registered compounding pharmacies and whether Certificates of Analysis are available for review.
Making an Informed Decision
The compounded tirzepatide situation is more nuanced than most internet articles suggest. It is not as simple as “order it online,” and it is not as scary as “it’s all being shut down.” The reality is somewhere in between, and it depends heavily on working with a knowledgeable, transparent provider who stays current with FDA guidance.
If you have been thinking about whether compounded tirzepatide is the right option for your weight loss goals, the best next step is a conversation with a licensed provider who can evaluate your specific situation. A telehealth consultation is designed to do exactly that: walk you through the process, answer your questions, and determine whether this medication fits your health profile. No pressure, no obligation. Just an honest clinical conversation about what makes sense for you.
The availability and legal status of compounded tirzepatide is subject to FDA regulation and may change. This article reflects information available at the time of publication. Always consult a licensed provider.